Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Cash from Operations (2018 - 2025)

Historic Cash from Operations for Serina Therapeutics (SER) over the last 8 years, with Q3 2025 value amounting to -$3.8 million.

  • Serina Therapeutics' Cash from Operations fell 2903.44% to -$3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$16.5 million, marking a year-over-year decrease of 3286.39%. This contributed to the annual value of -$17.1 million for FY2024, which is 59212.44% down from last year.
  • Latest data reveals that Serina Therapeutics reported Cash from Operations of -$3.8 million as of Q3 2025, which was down 2903.44% from -$3.8 million recorded in Q2 2025.
  • In the past 5 years, Serina Therapeutics' Cash from Operations registered a high of $121000.0 during Q4 2023, and its lowest value of -$8.0 million during Q2 2024.
  • In the last 5 years, Serina Therapeutics' Cash from Operations had a median value of -$1.7 million in 2021 and averaged -$2.4 million.
  • Per our database at Business Quant, Serina Therapeutics' Cash from Operations soared by 10915.97% in 2023 and then plummeted by 389256.2% in 2024.
  • Serina Therapeutics' Cash from Operations (Quarter) stood at -$1.6 million in 2021, then increased by 19.79% to -$1.3 million in 2022, then soared by 109.16% to $121000.0 in 2023, then crashed by 3892.56% to -$4.6 million in 2024, then increased by 16.71% to -$3.8 million in 2025.
  • Its Cash from Operations was -$3.8 million in Q3 2025, compared to -$3.8 million in Q2 2025 and -$4.3 million in Q1 2025.